#Brazil #São Paulo #CAR-T therapy #IASO Bio #Butantan Institute

IASO Bio Partners with Instituto Butantan for Innovative Cancer Therapy

In a significant development in the field of healthcare, IASO Biotechnology, known as IASO Bio, has entered into a groundbreaking technology licensing agreement with Brazil's esteemed Instituto Butantan. This partnership is dedicated to the local development of a CAR-T cell therapy targeting hematological cancer, leveraging the patient's own immune cells to combat this serious disease.

The agreement aims to address a major issue: the accessibility of advanced cancer treatments in Brazil. Currently, the CAR-T therapy can cost patients up to $500,000, and it is primarily available only through private healthcare channels. However, through this collaboration, IASO Bio and Instituto Butantan are setting the stage for a more cost-effective solution, one that could potentially be absorbed into Brazil's Unified Health System (SUS).

A Strategic Agreement for the Future of Healthcare
The technology will be developed and manufactured at the Nutera-SP Advanced Therapies Center in São Paulo, which is managed by the Butantan Institute and equipped specifically for cell therapy innovations. The focus on local production is expected to substantially lower costs, making treatment more accessible for Brazilian citizens.

The Director of the Butantan Institute, Esper Kallás, expressed optimism about the partnership, emphasizing that while CAR-T therapy has revolutionized the treatment landscape for hematological diseases, challenges around access still remain. He stated, “The new partnership allows the Butantan Institute, as a public institution, to expand its portfolio of advanced therapies to meet the needs of Brazilian public health.”

Milestone for Brazilian Science and Patient Care
Vanderson Rocha, a Full Professor of Hematology and coordinator of Nutera-SP, remarked on the historical significance of this collaboration for Brazilian science. He stated, “In the future, the therapy could expand treatment possibilities for patients who no longer respond to conventional therapies.” This sentiment of hope is echoed by many in the medical community who recognize the necessity of innovative approaches in healthcare delivery.

Jinhua Zhang, the Founder, Chairwoman, and CEO of IASO Bio, outlined the broader implications of the partnership, marking it as a pivotal milestone in IASO Bio’s global strategy. Zhang noted, “By combining our proprietary cell therapy technology with Butantan’s exceptional development and manufacturing capabilities, we have a unique opportunity to significantly reduce costs and make this life-saving treatment accessible to many more patients in Brazil.”

About IASO Bio
Founded in 2017, IASO Bio is making strides in the field of biopharmaceuticals, focusing on advanced therapy medicinal products (ATMP). It specializes in developing cell therapies and biologics designed to treat hematological malignancies and autoimmune diseases. With a fully integrated platform that covers the entire lifecycle—from research and development to manufacturing and commercialization—IASO Bio aims to bring cutting-edge innovations from China to the global market.

About the Butantan Institute
The Butantan Institute stands as the largest producer of vaccines and serums in Latin America, with a significant role in Brazil's healthcare sector. It is responsible for the majority of hyperimmune serums used to treat envenomation from venomous animals, bacterial toxins, and rabies virus, and notably, it produces all of Brazil’s influenza vaccines.

As both institutions look towards the future, the collaboration not only promises to enhance treatment options for patients battling hematological cancers but also aims to set a precedent for more collaborative public-health initiatives in Brazil and beyond.